01761nas a2200229   4500000000100000008004100001260003400042653005700076653001700133653002400150653002100174653002100195100001300216700001400229700001500243700001200258700001900270700001200289245008200301520112300383022002501506       2021                            d  bOxford University Press (OUP)10aPublic Health, Environmental and Occupational Health10aParasitology10aInfectious Diseases10aGeneral Medicine10aivermectin (IVM)1 aKositz C1 aBradley J1 aHutchins H1 aLast AR1 aD'Alessandro U1 aMarks M00aBroadening the range of use cases for ivermectin – a review of the evidence3 a<jats:title>Abstract</jats:title>
               <jats:p>Ivermectin is a broad-spectrum antiparasitic agent that interferes with glutamate-gated chloride channels found in invertebrates but not in vertebrate species. Mass drug administration (MDA) with ivermectin-based regimes has been a mainstay of elimination efforts targeting onchocerciasis and lymphatic filariasis for more than 3 decades. More recently, interest in the use of ivermectin to control other neglected tropical diseases (NTDs) such as soil-transmitted helminths and scabies has grown. Interest has been further stimulated by the fact that ivermectin displays endectocidal efficacy against various Anopheles species capable of transmitting malaria. Therefore there is growing interest in using ivermectin MDA as a tool that might aid in the control of both malaria and several NTDs. In this review we outline the evidence base to date on these emerging indications for ivermectin MDA with reference to clinical and public health data and discuss the rationale for evaluating the range of impacts of a malaria ivermectin MDA on other NTDs.</jats:p>  a0035-9203, 1878-3503